215 related articles for article (PubMed ID: 35734858)
41. Presence of risk factors associated with colectomy among patients with ulcerative colitis: a
Rubin DT; Salese L; Cohen M; Kotze PG; Woolcott JC; Su C; Mundayat R; Paulissen J; Torres J; Long MD
Therap Adv Gastroenterol; 2023; 16():17562848231189122. PubMed ID: 37560161
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.
Vermeire S; Su C; Lawendy N; Kobayashi T; Sandborn WJ; Rubin DT; Modesto I; Gardiner S; Kulisek N; Zhang H; Wang W; Panés J
J Crohns Colitis; 2021 Jul; 15(7):1130-1141. PubMed ID: 33290538
[TBL] [Abstract][Full Text] [Related]
43. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
[TBL] [Abstract][Full Text] [Related]
44. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Wang L; Chen C; Kwok K; Biswas P; Shapiro A; Madsen A; Wollenhaupt J
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33127856
[TBL] [Abstract][Full Text] [Related]
45. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
46. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
[TBL] [Abstract][Full Text] [Related]
47. Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.
Rubin DT; Torres J; Regueiro M; Reinisch W; Prideaux L; Kotze PG; Tan FH; Gardiner S; Mundayat R; Cadatal MJ; Ng SC
Crohns Colitis 360; 2024 Jan; 6(1):otae004. PubMed ID: 38425446
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Nash P; Coates LC; Fleishaker D; Kivitz AJ; Mease PJ; Gladman DD; FitzGerald O; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Kanik KS
Lancet Rheumatol; 2021 Apr; 3(4):e270-e283. PubMed ID: 38279411
[TBL] [Abstract][Full Text] [Related]
49. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
[TBL] [Abstract][Full Text] [Related]
50. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
51. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.
Deepak P; Alayo QA; Khatiwada A; Lin B; Fenster M; Dimopoulos C; Bader G; Weisshof R; Jacobs M; Gutierrez A; Ciorba MA; Christophi GP; Patel A; Hirten RP; Colombel JF; Rubin DT; Ha C; Beniwal-Patel P; Ungaro RC; Syal G; Pekow J; Cohen BL; Yarur A
Clin Gastroenterol Hepatol; 2021 Aug; 19(8):1592-1601.e3. PubMed ID: 32629130
[TBL] [Abstract][Full Text] [Related]
52. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.
Vavricka SR; Greuter T; Cohen BL; Reinisch W; Steinwurz F; Fellmann M; Guo X; Lawendy N; Paulissen J; Peyrin-Biroulet L
Therap Adv Gastroenterol; 2022; 15():17562848221090834. PubMed ID: 35574426
[TBL] [Abstract][Full Text] [Related]
53. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
54. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
[TBL] [Abstract][Full Text] [Related]
55. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
[TBL] [Abstract][Full Text] [Related]
56. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.
Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A
Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491
[TBL] [Abstract][Full Text] [Related]
57. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S
World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488
[TBL] [Abstract][Full Text] [Related]
58. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
59. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
[TBL] [Abstract][Full Text] [Related]
60. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
